A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers

Study category: Cancer

Is this Study for You?

Let's Get Started!




- pathologically confirmed biliary tract cancer, including IHC, EHC, and GBC - must have received at least 1 prior line of systemic therapy, and received no more than 2 prior lines of therapy in the metastatic setting (disease recurrence < 6 months from the last dose of adjuvant therapy in resected patients will be considered the first line of therapy) - patients with the following prior treatments are excluded / not eligible: - anti-CTLA-4, anti-PD-1, or anti-PD-L1or other immune checkpoint inhibitor therapeutic antibodies or pathway-targeting agents; - MEK or ERK inhibitors - patients with active, untreated brain mets will are not eligible

Type of Study



Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Sarah Davis,  MD

Sarah Davis, MD

Study ID

Protocol Number: 22-0030

More information available at ClinicalTrials.gov: NCT04941287


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers